Levothyroxine Potency Specs Should Be Narrower, Joint FDA Advisory Cmte. Says
This article was originally published in The Pink Sheet Daily
The potency specifications for the troubled levothyroxine should be narrowed from 90-110% to 95-105%, committee members recommend.
You may also be interested in...
Some manufacturers have been unable to demonstrate that their products have a two-year shelf life, the agency said.
Dr. Reddy's, GSK, Ranbaxy and UCB among manufacturers that could see prices reduced under government order that reflects issues raised in Gleevec patent dispute.
Indian regulators threaten compulsory licensing of the oncologic, but Novartis says it has no plans to end its bid for patent protection.